Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZ235 vs Everolimus in Advanced pNET
NCT01628913Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of dactolisib in Pancreatic neuroendocrine tumor (PanNET), sponsored by Novartis. Started Oct 2012; status: terminated.
02
Drugs
dactolisib
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01628913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01628913.